Jocelyn Marchiori, Andrea Sanchez, Kristen Messenger, Jennifer M. Reinhart, Hugues Beaufrère, Sonja Fonfara, Alexander Valverde, Yu Gu, Ron Johnson
{"title":"Pharmacokinetics of Intramuscular and Intravenous Glycopyrrolate in Juvenile New Zealand White Rabbits","authors":"Jocelyn Marchiori, Andrea Sanchez, Kristen Messenger, Jennifer M. Reinhart, Hugues Beaufrère, Sonja Fonfara, Alexander Valverde, Yu Gu, Ron Johnson","doi":"10.1111/jvp.70061","DOIUrl":null,"url":null,"abstract":"<p>Glycopyrrolate is an alternative to atropine to treat bradyarrhythmias in anesthetized rabbits; however, there are no pharmacokinetic studies in the literature. Six female New Zealand White rabbits received glycopyrrolate 0.05 mg/kg intravenously (IV) in the cephalic vein or intramuscularly (IM) in a complete crossover design. Blood was collected via jugular catheter to determine glycopyrrolate concentrations at baseline, 3, 5, 10, 20, 30, 45, 60 min and 2, 4, 6, 8, 12 and 24 h post-administration. Quantification of plasma glycopyrrolate was performed using liquid chromatography–tandem mass spectrometry. Non-compartmental analysis showed fast clearance (104.03 ± 45.55 mL/kg/min), volume of distribution at steady state of 0.75 ± 0.54 L/kg and terminal half-life of 2.49 ± 1.1 h after IV administration. Terminal half-life was 3.34 ± 1.10 h, T<sub>max</sub> was 0.07 ± 0.01 h, and C<sub>max</sub> was 2.96 ± 2 ng/mL for the IM route. Absolute bioavailability for the IM route was 10.07% ± 3.39%, suggesting higher doses may be needed for this route of administration. This study reports the pharmacokinetic parameters of glycopyrrolate in rabbits after IV and IM administration and may help design future evidence-based administration protocols in this species.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":"49 4","pages":"421-426"},"PeriodicalIF":1.4000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvp.70061","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvp.70061","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Glycopyrrolate is an alternative to atropine to treat bradyarrhythmias in anesthetized rabbits; however, there are no pharmacokinetic studies in the literature. Six female New Zealand White rabbits received glycopyrrolate 0.05 mg/kg intravenously (IV) in the cephalic vein or intramuscularly (IM) in a complete crossover design. Blood was collected via jugular catheter to determine glycopyrrolate concentrations at baseline, 3, 5, 10, 20, 30, 45, 60 min and 2, 4, 6, 8, 12 and 24 h post-administration. Quantification of plasma glycopyrrolate was performed using liquid chromatography–tandem mass spectrometry. Non-compartmental analysis showed fast clearance (104.03 ± 45.55 mL/kg/min), volume of distribution at steady state of 0.75 ± 0.54 L/kg and terminal half-life of 2.49 ± 1.1 h after IV administration. Terminal half-life was 3.34 ± 1.10 h, Tmax was 0.07 ± 0.01 h, and Cmax was 2.96 ± 2 ng/mL for the IM route. Absolute bioavailability for the IM route was 10.07% ± 3.39%, suggesting higher doses may be needed for this route of administration. This study reports the pharmacokinetic parameters of glycopyrrolate in rabbits after IV and IM administration and may help design future evidence-based administration protocols in this species.
期刊介绍:
The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.